Aldeyra Therapeutics, Inc. (ALDX)
NASDAQ: ALDX · Real-Time Price · USD
5.20
+0.08 (1.66%)
At close: Mar 4, 2026, 4:00 PM EST
5.20
0.00 (0.10%)
After-hours: Mar 4, 2026, 7:32 PM EST

Aldeyra Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-33.85-55.85-37.54-62.02-57.78
Depreciation & Amortization
0.250.250.260.260.26
Stock-Based Compensation
6.097.975.758.297.11
Other Adjustments
-0.66-1.490.340.280.41
Changes in Accounts Payable
-0.02-1.161.2-0.890.64
Changes in Accrued Expenses
-6.345-8.081.24.56
Changes in Unearned Revenue
--6--
Changes in Other Operating Activities
1.182.071.73-3.762.24
Operating Cash Flow
-33.35-43.21-30.33-56.64-42.56
Capital Expenditures
----0.02-0.01
Purchases of Investments
-40.26-96.92--92.94-
Proceeds from Sale of Investments
88523063-
Investing Cash Flow
47.74-44.9230-29.95-0.01
Long-Term Debt Repaid
--0.29-1.04--
Net Long-Term Debt Issued (Repaid)
--0.29-1.04--
Issuance of Common Stock
1.120.390.311.22194.5
Repurchase of Common Stock
---0.53--
Net Common Stock Issued (Repurchased)
1.120.39-0.231.22194.5
Other Financing Activities
--0.27---
Financing Cash Flow
1.12-0.17-1.271.22194.5
Net Cash Flow
15.51-88.3-1.6-85.37151.93
Free Cash Flow
-33.35-43.21-30.33-56.65-42.56
Free Cash Flow Per Share
-0.56-0.73-0.51-0.97-0.79
Levered Free Cash Flow
-38.77-49.98-37.46-65.23-50.08
Unlevered Free Cash Flow
-40.19-53.95-41.67-65.88-48.52
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q